ArticleNPJ precision oncology2024

Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations.

Sarina A Piha-Paul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.